Phase 3 Chronic Kidney Disease Trial, Recruiting NCT06982079 Sponsor: Ain Shams University Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT06982079
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older.
  • People with advanced chronic kidney disease (a kidney function level below a certain threshold, measured by a blood test) who are not currently on dialysis.

Who may not be able to join:

  • People diagnosed with a genetic kidney condition called autosomal dominant polycystic kidney disease (ADPKD), which causes cysts to grow on the kidneys.
  • People with Type 1 diabetes.
  • People currently taking a type of medication known as SGLT2 inhibitors (a class of tablets sometimes used for diabetes or kidney disease).
  • People who have had a serious condition called ketoacidosis (a dangerous build-up of acids in the blood) within the last 3 months.
  • People with a known allergic reaction or sensitivity to SGLT2 inhibitor medications.
  • People with known liver problems or liver disease.
  • People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in the eGFR slope; Time to start of renal replacement therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov